Document is current

Documents that mention this clinical trial

Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9537

538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
https://doi.org/10.1136/jitc-2021-sitc2021.538

868 Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels
https://doi.org/10.1136/jitc-2021-sitc2021.868

571 IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells
https://doi.org/10.1136/jitc-2021-sitc2021.571

619 Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma
https://doi.org/10.1136/jitc-2022-sitc2022.0619

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

819 Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp
https://doi.org/10.1136/jitc-2021-sitc2021.819

959 Tebentafusp controls disease and prolongs survival by increasing the T cell: tumor cell ratio, activating T cells and inhibiting tumor proliferation in metastatic uveal melanoma patients
https://doi.org/10.1136/jitc-2025-sitc2025.0959

1108 Novel regulators of ImmTAC-mediated killing of melanoma cancer cells revealed by genome-wide CRISPR-Cas9 screens
https://doi.org/10.1136/jitc-2023-sitc2023.1108

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
https://doi.org/10.1136/jitc-2024-009028

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
https://doi.org/10.1200/jco.2024.42.16_suppl.9529